Alpine Immune Sciences presents data for povetacicept in SLE at ACR Convergence

Alpine Immune Sciences announced that the Company presented new translational data for povetacicept in systemic lupus erythematosus or SLE at the American College of Rheumatology Convergence 2023..Povetacicept Presentation Highlights Include: In SLE patients, BAFF- and APRIL-related genes are increased in myeloid lineage cells and B cells compared to healthy adults. Povetacicept, as compared to single BAFF or APRIL pathway inhibitors, more potently downregulates genes associated with activation in B cells. Povetacicept significantly reduces multiple disease parameters in a mouse model of lupus, more effectively than WT TACI-Fc or conventional B cell depletion.